RAB19

Across TCGA pan-cancer cohorts, RAB19 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAB19 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RAB19 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAB19 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where RAB19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.470	0.289	.007	31	view →
CCRCC	DFS	Median	All	1.000	0.646	.021	7	view →
UCEC	DFS	Tertile	All	0.962	0.817	.028	4	view →
LUAD	OS	Tertile	II,III,IV	0.365	0.879	.033	4	view →
LSCC	OS	Median	All	0.668	0.880	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAB19–PDAC (DFS)

Open the PDAC breakdown →